These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23645657)

  • 1. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
    Shoji J; Lew SQ
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
    Bartel C; Obermüller N; Rummel MJ; Geiger H; Hauser IA
    Clin Nephrol; 2008 Apr; 69(4):285-9. PubMed ID: 18397703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
    Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
    Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
    Friedberg JW
    Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
    [No Abstract]   [Full Text] [Related]  

  • 6. Huge kidneys in a patient with chronic lymphocytic leukaemia.
    Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
    Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia accompanied by renal failure].
    Dzhumbaeva BT; Biriukova LS; Gemdzhian EG; Kravchenko SK; Melikian AL; Roshtina LS
    Ter Arkh; 2014; 86(12):37-41. PubMed ID: 25804038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
    Seipelt G; Böhme A; Koschmieder S; Hoelzer D
    Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
    Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
    Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
    Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
    Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
    Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
    Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
    Ujjani C; Cheson B
    Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
    Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
    Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
    [No Abstract]   [Full Text] [Related]  

  • 15. Making advances in first-line chronic lymphocytic leukemia treatment.
    Wierda WG
    J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
    Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
    Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
    Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
    Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
    Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.